NEWS & EVENTS

Latest news and upcoming events

09 Sep 2021

Ysios Capital achieves Certification under the Diversity VC Standard

Upcoming events
  • Jefferies London Healthcare Conference
    16 November – 18 Nov. 2021,
    London

  • LSX World Congress
    8 February – 9 February 2022,
    London

Ysios Capital’s portfolio company CVRx Inc. prices IPO on NASDAQ

This is a major achievement for Ysios as CVRx is its fifth portfolio company to be listed on NASDAQ, and the second within just three months.

AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial

REVIVAL study is evaluating ilofotase alfa, the Company’s proprietary recombinant human alkaline phosphatase, for the treatment of sepsis-associated acute kidney injury (SA-AKI).

Aura Biosciences Assembles New Bladder Cancer Focused Scientific Advisory Board

The new SAB will be comprised of seven members and will work closely with Aura’s senior management.

AM-Pharma Appoints Martijn Negen as VP Commercial Strategy

Martijn Negen has over 20 years of experience in pharmaceutical, biotech and diagnostic companies.

VarmX appoints Dr. Jan Öhrström as CEO, and Dr. Alex Gold to Supervisory Board

VarmX today announces the appointment of Dr. Gerard Short, MBBS, as Chief Medical Officer (CMO).

CorWave Successfully Performed a 90-Day In Vivo Study on Its Revolutionary Cardiac Pump Synchronized With the Native Heart, Results Presented at ASAIO Meeting

These data confirmed the ability of the CorWave pump to provide chronic circulatory support with exceptional hemocompatibility.

CorWave Successfully Performed a 90-Day In Vivo Study on Its Revolutionary Cardiac Pump Synchronized With the Native Heart, Results Presented at ASAIO Meeting

The results of the 90-day in vivo study were reported during an oral presentation entitled "Design Optimization of the CorWave Membrane LVAD."

OxThera reports results from Phase 3 ePHex study with Oxabact in primary hyperoxaluria patients with maintained kidney function

OxThera AB, announces completion of its pivotal Phase 3 study and reports top line results.

Aura Biosciences Appoints Sapna Srivastava, Ph.D., to its Board of Directors

Dr. Srivastava is currently the Chief Financial and Strategy Officer at eGenesis.

Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journal

Published results show efficacy in both adrenomyeloneuropathy (AMN) and cerebral ALD (cALD) related models.

Newsletter

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.